Depatuxizumab Mafodotin (ABT-414) is an antibody drug conjugate (ADC) targeting EGFR that is being investigated to treat 1L and 2L glioblastoma (GBM) and solid tumors.

Type of Molecule

Biologic

Target

EGFR

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Glioblastoma (GBM) New Indication Phase 2
Pediatric Brain Tumors New Indication Phase 1